HELP:NASDAQ
Cybin Inc
11,74 US$
arrow_downward
-1,47%(-0,18) 1D
2 ოქტ, 10:46:04 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for HELP...
Open
12,30 US$
High
12,30 US$
Low
11,59 US$
Avg. vol.
1,73 მლნ.
Volume
315,18 ათ.
52-wk high
15,15 US$
52-wk low
3,76 US$
Shares outstanding
73,06 მლნ.
No. of employees
100
Open
12,30 US$
High
12,30 US$
Low
11,59 US$
Avg. vol.
1,73 მლნ.
Volume
315,18 ათ.
52-wk high
15,15 US$
52-wk low
3,76 US$
Shares outstanding
73,06 მლნ.
No. of employees
100
News stories
From web sources and news partners
Investing.com Canada
·
12 საათის წინ
Form 4 Helus Pharma Inc. For: 1 October By Investing.com
MarketBeat
·
13 საათის წინ
Insider Buying: Cybin (NASDAQ:HELP) CFO Acquires 3,000 Shares of Company Stock
TipRanks
·
1 დღის წინ
Helus Pharma Finalizes Legal Name Change as It Prepares for Commercial Push
Profile
Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that was led by CEO Doug Drysdale from 2020-2025, developing psychedelic drugs as medicines.
The company's drug candidates include psilocybin, HLP002, deupsilocin, deudimethyltryptamine, HLP005, and HLP006. Another drug that the company has developed is CYB210010.
As of January 2025, deupsilocin is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development.
In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics. In late 2023, it acquired Small Pharma, the developer of SPL026 and SPL028. Helus Pharma was originally known as Cybin but changed its name in December 2025. Wikipedia
About Cybin Inc
CEO-
Employees100
Founded2019
Headquartersტორონტო, ონტარიო, კანადა
SectorPharmaceutical industry
Websitehelus.com